日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease

格卡瑞韦/哌仑他韦在患有慢性基因1-6型丙型肝炎病毒感染和代偿性肝病的成人中的安全性和药代动力学

期刊:Clinical Infectious Diseases
影响因子:7.3
doi:10.1093/cid/ciz022
Gane, Edward; Poordad, Fred; Zadeikis, Neddie; Valdes, Joaquin; Lin, Chih-Wei; Liu, Wei; Asatryan, Armen; Wang, Stanley; Stedman, Catherine; Greenbloom, Susan; Nguyen, Tuan; Elkhashab, Magdy; Wörns, Marcus-Alexander; Tran, Albert; Mulkay, Jean-Pierre; Setze, Carolyn; Yu, Yao; Pilot-Matias, Tami; Porcalla, Ariel; Mensa, Federico J
炎症/感染
肝炎
微生物学
发表日期：2019
文献求助 收藏

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

对接受奥比他韦和帕瑞他韦/利托那韦治疗的日本患者的丙型肝炎病毒2型基因型进行耐药性特征分析

期刊:Journal of Medical Virology
影响因子:4.6
doi:10.1002/jmv.24923
Schnell, Gretja; Tripathi, Rakesh; Krishnan, Preethi; Beyer, Jill; Reisch, Thomas; Irvin, Michelle; Dekhtyar, Tatyana; Setze, Carolyn; Rodrigues, Lino Jr; Alves, Katia; Burroughs, Margaret; Redman, Rebecca; Chayama, Kazuaki; Kumada, Hiromitsu; Collins, Christine; Pilot-Matias, Tami
微生物学
肝炎
发表日期：2018
文献求助 收藏

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

对接受帕立普韦-利托那韦和奥比他韦治疗的日本患者中丙型肝炎病毒1b基因型耐药变异株的分析

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/AAC.02606-15
Krishnan, Preethi; Schnell, Gretja; Tripathi, Rakesh; Beyer, Jill; Reisch, Thomas; Zhang, Xinyan; Setze, Carolyn; Rodrigues, Lino Jr; Burroughs, Margaret; Redman, Rebecca; Chayama, Kazuaki; Kumada, Hiromitsu; Collins, Christine; Pilot-Matias, Tami
微生物学
肝炎
发表日期：2016
文献求助 收藏

Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients

一项针对既往接受过治疗的丙型肝炎病毒感染患者的随机试验，研究不含干扰素和利巴韦林的奥比他韦/帕瑞他韦/利托那韦方案的疗效

期刊:Hepatology
影响因子:15.8
doi:10.1002/hep.27705
Chayama, Kazuaki; Notsumata, Kazuo; Kurosaki, Masayuki; Sato, Ken; Rodrigues, Lino Jr; Setze, Carolyn; Badri, Prajakta; Pilot-Matias, Tami; Vilchez, Regis A; Kumada, Hiromitsu
炎症/感染
肝炎
微生物学
发表日期：2015
文献求助 收藏

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis

一项针对感染丙型肝炎病毒基因1b型的日本患者（伴或不伴肝硬化）的随机3期临床试验，评估了ombitasvir/paritaprevir/ritonavir联合用药的疗效。

期刊:Hepatology
影响因子:15.8
doi:10.1002/hep.27972
Kumada, Hiromitsu; Chayama, Kazuaki; Rodrigues, Lino Jr; Suzuki, Fumitaka; Ikeda, Kenji; Toyoda, Hidenori; Sato, Ken; Karino, Yoshiyasu; Matsuzaki, Yasushi; Kioka, Kiyohide; Setze, Carolyn; Pilot-Matias, Tami; Patwardhan, Meenal; Vilchez, Regis A; Burroughs, Margaret; Redman, Rebecca
炎症/感染
肝炎
肝硬化
微生物学
发表日期：2015
文献求助 收藏

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A

丙型肝炎病毒 NS5A 抑制剂奥比他韦的体外和体内抗病毒活性及耐药性特征

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.1
doi:10.1128/AAC.04226-14
Preethi Krishnan, Jill Beyer, Neeta Mistry, Gennadiy Koev, Thomas Reisch, David DeGoey, Warren Kati, Andrew Campbell, Laura Williams, Wangang Xie, Carolyn Setze, Akhteruzzaman Molla, Christine Collins, Tami Pilot-Matias
免疫
微生物学
肝炎
发表日期：2015
文献求助 收藏